RCUS logo

RCUS
Arcus Biosciences Inc

1,775
Mkt Cap
$3.14B
Volume
549.00
52W High
$28.72
52W Low
$7.91
PE Ratio
-7.84
RCUS Fundamentals
Price
$24.95
Prev Close
$25.00
Open
$25.51
50D MA
$23.43
Beta
1.50
Avg. Volume
1.31M
EPS (Annual)
-$3.29
P/B
5.98
Rev/Employee
$410,981.70
$1,776.34
Loading...
Loading...
News
all
press releases
Arcus Biosciences (NYSE:RCUS) Issues Earnings Results
Arcus Biosciences (NYSE:RCUS - Get Free Report) posted its earnings results on Tuesday. The company reported ($1.02) EPS for the quarter, missing the consensus estimate of ($0.92) by ($0.10). Arcus...
MarketBeat·9d ago
News Placeholder
More News
News Placeholder
Arcus Biosciences, Inc. (RCUS) Reports Q1 Loss, Beats Revenue Estimates
Arcus Biosciences (RCUS) delivered earnings and revenue surprises of -10.87% and +21.43%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks·10d ago
News Placeholder
Arcus Biosciences Reports First-Quarter 2026 Financial Results and Provides a Pipeline Update
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and...
Business Wire·10d ago
News Placeholder
Arcus Biosciences (NYSE:RCUS) Rating Increased to Strong-Buy at Truist Financial
Truist Financial raised Arcus Biosciences to a "strong-buy" rating in a report on Monday...
MarketBeat·10d ago
News Placeholder
Eton Pharmaceuticals (ETON) Surges 19.8%: Is This an Indication of Further Gains?
Eton Pharmaceuticals (ETON) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Zacks·11d ago
News Placeholder
Apellis Pharmaceuticals, Inc. (APLS) Expected to Beat Earnings Estimates: Should You Buy?
Apellis Pharmaceuticals (APLS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·16d ago
News Placeholder
Arcus Biosciences (RCUS) to Release Quarterly Earnings on Tuesday
Arcus Biosciences (NYSE:RCUS) will be releasing its Q1 2026 earnings after the market closes on Tuesday, May 5. (View Earnings Report at...
MarketBeat·17d ago
News Placeholder
Arcus Biosciences, Inc. (RCUS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Arcus Biosciences (RCUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·17d ago
News Placeholder
Arcus Biosciences Announces New Employment Inducement Grants
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and...
Business Wire·21d ago
News Placeholder
Arcus Biosciences (NYSE:RCUS) Hits New 1-Year High - Should You Buy?
Arcus Biosciences (NYSE:RCUS) Hits New 1-Year High - What's Next...
MarketBeat·22d ago
<
1
2
...
>

Latest RCUS News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.